CAMP · CAMP4 Therapeutics Corporation

CAMP4 Therapeutics reported its first quarter 2026 financial results, highlighting a net loss of $18.3 million compared to $12.4 million in the same period last year. The increase was primarily driven by a $6.2 million non-cash loss recognized due to a change in fair value of the derivative tranche liability related to the September private placement. Revenue from research and collaboration increased to $1.3 million from $0.9 million. Operating expenses remained relatively flat, with R&D expenses of $10.2 million (vs. $10.1 million) and G&A expenses of $4.2 million (vs. $3.8 million), the latter driven by higher stock-based compensation and professional fees. Cash and cash equivalents stood at $99.2 million as of March 31, 2026, down from $109.5 million at year-end 2025, but the company expects this runway to fund operations into 2028. Key corporate highlights include the submission of the first regulatory filing for CMP-002 in Australia, with a global Phase 1/2 trial anticipated in the second half of 2026, and receipt of Orphan Designation from the EMA. Management emphasized progress toward initiating clinical trials for SYNGAP1-related disorder. The company also entered a collaboration with CURE SYNGAP1 to support the ProMMiS natural history study. These developments underscore CAMP4's focus on advancing its lead candidate while maintaining a solid cash position.